Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
MAGNA intends to show that the combination of pseudoephedrine, chlorpheniramine, plus a small
amount of belladonna alkaloid is a comprehensive, safe and effective twice daily (BID) drug
treatment for seasonal allergic rhinitis (SAR) patients with post-nasal drip (PND). The phase
1 single-dose trial will consist of 21 subjects: 1) to gather pharmacodynamic measurements
and blood levels of active ingredients over 12 hours; 2) To report subjective scores by
subjects rating efficacy of single dose of STAHIST; 3) To report any side effects or adverse
drug reactions and rate the severity of incidence.